Somatic missense mutations in PIK3CA, which encodes the p110a catalytic subunit of phosphoinositide 3-kinases, occur frequently in human cancers. Activating mutations spread across multiple domains, some of which are located at inhibitory contact sites formed with the regulatory subunit p85a. PIK3R1, which encodes p85a, also has activating somatic mutations. We find a strong correlation between lipid kinase and lipid-binding activities for both wild-type (WT) and a representative set of oncogenic mutant complexes of p110a/p85a. Lipid binding involves both electrostatic and hydrophobic interactions. Activation caused by a phosphorylated receptor tyrosine kinase (RTK) peptide binding to the p85a N-terminal SH2 domain (nSH2) induces lipid binding. This depends on the polybasic activation loop as well as a conserved hydrophobic motif in the C-terminal region of the kinase domain. The hotspot E545K mutant largely mimics the activated WT p110a. It shows the highest basal activity and lipid binding, and is not significantly activated by an RTK phosphopeptide. Both the hotspot H1047R mutant and rare mutations (C420R, M1043I, H1047L, G1049R and p85a-N564D) also show increased basal kinase activities and lipid binding. However, their activities are further enhanced by an RTK phosphopeptide to levels markedly exceeding that of activated WT p110a. Phosphopeptide binding to p110b/ p85a and p110d/p85a complexes also induces their lipid binding. We present a crystal structure of WT p110a complexed with the p85a inter-SH2 domain and the inhibitor PIK-108. Additional to the ATP-binding pocket, an unexpected, second PIK-108 binding site is observed in the kinase C-lobe. We show a global conformational change in p110a consistent with allosteric regulation of the kinase domain by nSH2. These findings broaden our understanding of the differential biological outputs exhibited by distinct types of mutations regarding growth factor dependence, and suggest a two-tier classification scheme relating p110a and p85a mutations with signalling potential.
Introduction
Class IA phosphoinositide 3-kinases (PI3Ks) transduce growth factor signalling by phosphorylating phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P 2 ) to produce PtdIns(3,4,5)P 3 on the plasma membrane. Recruitment to membrane receptors and enzyme activation are coordinated by engagement of the p85 SH2 domains to regions bearing phosphorylated 'YXXM' motifs on activated receptor tyrosine kinases (RTKs) or RTKassociated adaptors (Backer et al., 1992; Carpenter et al., 1993) . PtdIns(3,4,5)P 3 serves as docking sites for downstream signalling molecules that harbour pleckstrin homology domains. Central among these are PDK1 and PKB/AKT, which orchestrate signalling cascades promoting cell growth, proliferation, survival, metabolism and migration (Manning and Cantley, 2007; Franke, 2008; Bayascas, 2010) . Cellular levels of PtdIns(3,4,5)P 3 are tightly regulated. PTEN downregulates p110 signalling by removing the 3 0 -phosphate of PtdIns(3,4,5)P 3 (Carracedo and Pandolfi, 2008) . Upregulation of PI3K signalling, through amplification or gain-of-function mutations of RTKs, p110a and AKTs, as well as loss of PTEN function and expression, occurs frequently in human cancers (Yuan and Cantley, 2008; Chalhoub and Baker, 2009) .
Uniquely among the four class I PI3K isoforms that produce PtdIns(3,4,5)P 3 , p110a has been identified with activating cancer-linked somatic mutations (Samuels et al., 2004) . Over 80% of the missense mutations cluster in two 'hotspots' commonly represented by E545K in the helical domain and H1047R in the kinase domain. Both display transforming activities in cell culture (Zhao et al., 2005; Gymnopoulos et al., 2007) . The ability to initiate tumourigenesis in transgenic mouse models has been demonstrated for the H1047R mutant (Engelman et al., 2008; Adams et al., 2011; Meyer et al., 2011) .
Crystal structures of p110a/85a complexes have provided molecular details of p85-mediated inhibition (Huang et al., 2007; Mandelker et al., 2009) , revealing that many activating mutations, including ones occurring at low frequencies (Ikenoue et al., 2005; Gymnopoulos et al., 2007; Oda et al., 2008; Zhang et al., 2008; Jaiswal et al., 2009; Rudd et al., 2011) , are located in inter-domain contact sites. These sites include the inhibitory interfaces between the p110a C2/helical/ kinase domains and the p85a N-terminal SH2 domain (nSH2; Miled et al., 2007; Mandelker et al., 2009) , and between the p110a C2 domain and the p85a-inter-SH2 (iSH2) domain . Phosphopeptide binding to nSH2 competes with its inhibitory interaction with p110, constituting the dominant activation mechanism for p110a, and E545K mimics this activation (Yu et al., 1998; Miled et al., 2007; Mandelker et al., 2009) . As p110a adaptor-binding domain (ABD) binds to p85a-iSH2 tightly, the often-mutated interface between adaptor-binding domain and the kinase domain can be viewed as an extension of the p85 inhibitory network. Mutations in the kinase C-terminal region do not appear to interfere with p85 inhibition, as p85a cSH2 does not have an inhibitory role in p110a regulation (Yu et al., 1998) , although it does for p110b and p110d via direct contact with this region (Burke et al., 2011; Zhang et al., 2011) .
Some of the cancer-linked mutations confer a positive charge, such as C420R and H1047R in p110a, and have been suggested to enhance membrane binding (Gymnopoulos et al., 2007; Mandelker et al., 2009) . However, direct membrane-binding measurements are lacking. A common assumption is that these mutations directly facilitate electrostatic interaction with phospholipid headgroups. However, this has limited applicability to other activating mutations, notably H1047L. The E545K and H1047R mutants were first reported to have similar biological activities, in terms of promoting cell growth and resisting apoptosis under growth factor limiting conditions (Samuels et al., 2005) . More recent studies showed that they can have differential functional outcomes, in terms of chemotactic and metastatic phenotypes (Pang et al., 2009 ) and transforming potential (Chakrabarty et al., 2010) of isogenic human breast cancer cells. Transforming ability of chicken embryonic fibroblasts differs between the E545K and the H1047R mutants, invoking the suggestion that these two mutants operate via different activation mechanisms (Zhao and Vogt, 2008) .
Previously, the E545K and H1047R mutants were found to be more active than the wild-type (WT) enzyme, but their similar affinities for ATP did not explain the differences in lipid kinase activities (Carson et al., 2008) . Here, we investigated the premise that enhanced lipid binding forms a general mechanism for p110 activation, particularly regarding cancer mutations. We dissected the structural elements important for lipid binding. Our results show that p85a nSH2, a key regulatory element for p110a lipid kinase activity, controls access of the catalytic subunit lipid-binding sites to membrane. We examined a set of p110a/p85a cancer-linked mutants of diverse structural and chemical types, and find a strong correlation linking their elevated lipid kinase activities to their lipid-binding levels. We present a crystal structure of WT p110a/p85a-iSH2 in complex with an inhibitor. Its structural features in the kinase domain resemble those of the H1047R mutant (Mandelker et al., 2009) , instead of the WT apo structure (Huang et al., 2007) . We also noted unusual structural features of the kinase C-terminal tail and tested their function. We observe global conformational changes that might be of relevance to allosteric regulation of p110a, and provide a structural context to understand the functional data presented here.
Results
Structure of a WT p110a/p85a-iSH2 complex A crystal structure of mouse WT p110a in complex with human p85a-niSH2 fragment and the p110b/p110d-selective inhibitor PIK-108 has been determined and refined to 3.5 Å (R work /R free ¼ 0.184/0.228; acronyms of p110a and p85a domain structures and mutations are illustrated in Figure 1 ). Details of crystallographic statistics are provided in Supplementary Table S1 . Although other compounds that inhibit p110a more specifically were surveyed for co-crystallization, the p110b/d-selective PIK-108 produced the best crystals. As in the structure of human WT p110a/p85a-iSH2 (Huang et al., 2007) , the nSH2 of the p85a-niSH2 fragment is not observed in the electron density map. The high salt concentration in the crystallization cocktail might have competed off nSH2 binding to p110a. As such, our structure represents an alternative view of p110a not constrained by nSH2 binding. Unlike previous structures of p110a/p85a complexes, our structure shows clear electron density for the entire activation loop (Figure 2a ). However, key conserved activation loop residues, K942 and R949, previously identified to be important for p110g recognizing the substrate PtdIns(4,5)P 2 headgroup (Pirola et al., 2001) , point away from the ATP-binding site (Figure 2d ). Hence, although structure of a p110a/p85a-iSH2 complex should mimic an RTK-activated state (see below), the observed conformation of this loop does not appear to be compatible with positioning the lipid headgroup for phosphoryl transfer. The activation loop is also involved in crystal contacts (Supplementary Figure S1) , which likely influenced the conformation that we observe.
PIK-108 belongs to the class of propeller-shaped PI3K inhibitors. In our structure, the PIK-108 phenyl substituent occupies what has been coined the 'specificity pocket', which is gated by the P-loop M772, in the kinase ATP-binding site (Figure 2b ). Opening of this pocket by propeller-shaped compounds appears to be more favourable in p110d than in other p110 isotypes (Berndt et al., 2010) . This could be the reason for the PIK-108 selectivity for p110b and p110d. There is also complete density for what we interpret as a second PIK-108, snuggling in a hydrophobic pocket in the kinase C-lobe, surrounded by helices ka6-8, ka11 (hereafter all p110 secondary structure nomenclature is according to that of p110g (Walker et al., 1999) ) and the C-terminal end of the activation loop (Figure 2c ). This pocket is partially occupied by the activation loop residues 954-956 (or their equivalents) in other p110 structures. The presence of the compound in this induced pocket may have contributed to the ordering of the activation loop, which is involved in crystal packing, and might explain why this crystal form is specific to PIK-108, out of 20 tested p110-selective inhibitors.
The kinase C-terminal region of p110a exhibits intrinsic flexibility Our structure is for the WT p110a, but the kinase C-terminal tail more closely resembles those in the structures of the oncogenic mutant H1047R p110a/ p85a-niSH2 (Mandelker et al., 2009) , than those in the WT apo p110a/p85a-iSH2 structure (Huang et al., 2007) . In the WT apo p110a/p85a-iSH2 structure, helix ka11 is complete to residue 1048, and the rest of the C-terminal sequence is largely disordered (Huang et al., 2007) . The kinase C-terminal tail in our structure adopts an extended conformation from residue 1045 to 1061, with the last helical turn of ka11 appearing to be distorted (Figure 2a) . A striking feature in this region is the WIF motif (1057-1059), whose side chains stack against each other (Figure 2d ). This motif is conserved as a triplet of hydrophobic residues in class I and class II PI3Ks, with W1057 being invariant in class I p110 (Figure 1 ). The equivalent 'WFL' (1086-1088) in p110g is part of helix ka12 (Figure 2e ), which corresponds to residues 1050-1061 in p110a. Helix ka12 also exists in the crystal structures of p110b and Vps34 Zhang et al., 2011) . This C-terminal region in our structure, and also in the H1047R p110a/p85a-niSH2 structures, is involved in crystal packing with the Rasbinding domain of a symmetry-related molecule (Supplementary Figure S1 ). Therefore, the conformations of the C-terminal tail among the current p110a structures appear to be dictated by the crystalline environments. It is likely fortuitous that the Ras-binding domain and the kinase domain pack against each other in different crystal forms of p110a. We would not ascribe any functional significance to these crystal contacts, particularly with regard to Ras activation.
Deletion of helix ka12 in Vps34, p110b and p110d abrogated lipid kinase activity and lipid binding Burke et al., 2011; Zhang et al., 2011) . This region is also of functional importance for p110a (see below). Deletion of ka12 in Vps34 and in p110b resulted in increased intrinsic ATPase activity in the absence of lipid substrate Zhang et al., 2011) , an observation replicated by deletion of residues 1051-1068 in p110a (Supplementary Figure S2 , Dcterm mutant). Interactions between helix ka12 and the catalytic loop (illustrated for p110g in Figure 2e ) were suggested to shield the conserved catalytic DRH motif from performing futile ATP Figure 1 Schematics of p110a and p85a domain structures. Substitution and deletion mutants used in this study are illustrated. Sequence alignment display was prepared with Jalview (Waterhouse et al., 2009) . Basic residues in the activation loop (which binds the lipid substrate headgroup) and hydrophobic residues in the C-terminal tail are highlighted. ABD, adaptor-binding domain; RBD, Ras-binding domain.
Lipid binding of oncogenic mutants of PI3-kinases W-C Hon et al hydrolysis Zhang et al., 2011) . These interactions are not observed in the current p110a crystal structures, suggesting that in solution p110a could also have a helix ka12, similar to p110g, p110b and Vps34. The extended conformations observed in current crystal structures of p110a suggest an intrinsic flexibility in this region. The initial rates of PtdIns(3,4,5)P 3 production were measured with fixed substrate concentration (50 mM PtdIns(4,5)P 2 and 100 mM ATP) using liposomes of the indicated compositions. No lipid kinase activity was detected for the lipid kinase-dead mutants, which were active in hydrolysing ATP in the absence of lipid substrate. (g, h, j) Lipid binding measured by SPR. Binding levels were compared at identical protein concentration in each set (g, j: 500 nM, h: 1 mM). Averaged binding levels of the lipid kinase-dead mutants on Fc1, B35 RU, were taken as the estimated bulk contribution, that is, refractive index change due to the presence of proteins in the buffer (h). Data in f-j represent the mean ± s.d. of two to three independent experiments. PC, phosphatidylcholine; PE, phosphatidylethanolamine; PIP2, PtdIns(4,5)P 2 ; PIP3, PtdIns(3,4,5)P 3 ; pY2, pY2-peptide with two pYXXM motifs from platelet-derived growth factor receptor-b (PDGFR-b).
C-terminal tail

Correlation of lipid kinase activity with lipid binding
To test whether lipid binding forms the basis of p110 activation, we compared lipid kinase with lipid-binding activities for three sets of p110a/p85a complexes: SH2 deletions in p85a, engineered mutations in the p110a kinase domain and cancer-linked mutations in both p110a and p85a (Figure 3 ). We evaluated activation by RTK phosphopeptide for all complexes using the doubly tyrosine-phosphorylated peptide (pY2-peptide) derived from platelet-derived growth factor receptor-b (PDGFR-b). We used liposomes of defined compositions generally mimicking that of plasma membranes (Narayan and Lemmon, 2006) . The substrate PtdIns(4,5)P 2 was used at 2% (close to the physiological concentration), and the anionic lipid phosphatidylserine (PS) was tested at two concentrations, 10% and 20%. Cancer-linked mutations and nSH2 deletion in p85a severely suppressed expression of p110/p85 in insect cells. To obtain sufficient materials for lipid-binding analyses, we produced activating p110a/p85a proteins in the catalytically dead (CD) background, bearing the D915N mutation in the catalytic DRH motif of p110a.
We employed surface plasmon resonance to measure lipid binding (schematics shown in Figures 3d  and e) . We examined the electrostatic and the hydrophobic components of lipid binding explicitly, as both are important properties for many membranebinding proteins (Cho and Stahelin, 2005; Lemmon, 2008) . We immobilized liposomes of different compositions in each of the four serially connected flow cells on the sensor chip. Flow cell one (Fc1) of the chip contained only neutral lipids phosphatidylcholine, phosphatidylethanolamine and cholesterol, whereas Fc2, Fc3 and Fc4 contained additionally negatively charged lipids PS (Fc2) or PS with PtdIns(4,5)P 2 (Fc3 and Fc4). As such, Fc1-subtracted signals represent the electrostatic component of binding. We attribute any binding signals on Fc1 that are significantly above background (estimated as the averaged signal on Fc1 produced by the lipid kinase-dead mutants) to be the hydrophobic component of lipid binding. p85a nSH2, but not cSH2, regulates both lipid kinase activity and membrane binding of p110a The nSH2 has a dominant role in regulating the lipid kinase activity of p110a. The basal activities of p110a/ p85a-nicSH2 and p110a/p85a-niSH2 complexes are very low using liposome substrate mimicking physiological concentrations of PS and PtdIns(4,5)P 2 . Activation, whether by binding of RTK phosphopeptide to nSH2-containing complexes or by nSH2 deletion, increases the activity by 25-to 50-fold (Figure 3f) . Qualitatively, our results recapitulate those of previous studies performed with pure PtdIns as substrate (Yu et al., 1998) . Correspondingly, RTK phosphopeptide binding to nSH2-containing complexes induces lipid binding (Figure 3g ). Binding of RTK phosphopeptide to cSH2 does not affect either the kinase activity or membrane binding (Figures 3f and g ). Total negative charge on the liposomes positively influenced lipid binding. Liposome compositions differing by 10% in PS confer up to twofold increases in lipid-binding levels. Hence, it appears that for p110a, the nSH2-p110a inhibitory contact, which is relieved by phosphopeptide binding, suppresses the basal lipid kinase activity by inhibiting membrane binding.
Both kinase activation loop and C-terminal tail are necessary for binding to anionic lipids Using PtdIns(4,5)P 2 -containing liposomes, no kinase activity could be detected for three engineered kinase domain mutants: (1) the activation loop mutant R949D, (2) the kinase helix ka12 deletion mutant (Dcterm) nor (3) a helix ka12 triple mutant with much reduced hydrophobicity (WIF-AAA(1057-1059)), with protein concentration as high as 500 nM and incubation time up to an hour. These mutants, however, are catalytically active in terms of intrinsic ATPase activity (Supplementary Figure S2 ). In lipid-binding experiments, correspondingly, the R949D mutant showed much reduced binding to anionic lipids (Figure 3h ). The same result was observed for K942Q (data not shown). These results are consistent with the observation that mutations removing the positive charges of the equivalent residues in p110g prevent PtdIns(4,5)P 2 , but not PtdIns or PtdIns4P, from acting as a substrate (Pirola et al., 2001) . The kinase C-terminal mutants, Dcterm and WIF-AAA, did not show any detectable binding to anionic lipids at concentration up to 1 mM. This establishes the WIF motif as a key determinant for lipid binding in the C-terminal region. These results indicate that there are at least two lipid-binding sites in the kinase domain: one is in the polybasic activation loop, electrostatic in nature, and the other in the C-terminal region, hydrophobic in nature.
Effects of cancer-linked mutations in p110a/p85a on lipid binding To gain a broader view of the effects of cancer-linked mutations, we studied seven mutations that have previously been characterized to be activating (Ikenoue et al., 2005; Gymnopoulos et al., 2007; Zhang et al., 2008; Jaiswal et al., 2009) . They cover three structurally distinct regions (Figures 3a-c) , namely, the C2-iSH2 interface (p110a C420R and p85a-N564D), the helicalnSH2 interface (p110a E545K) and the kinase domain (M1043I, H1047L, H1047R and G1049R), and represent different chemical property changes.
Overall, there is a strong correlation between lipid kinase activity and lipid binding (Figures 3i and j , total lipid binding on Fc4 is shown in Supplementary  Figure S3 ), underscoring enhanced lipid binding as a general mechanism for cancer-linked activating mutations. All mutants have increased basal activity, and other than E545K, can be significantly further activated by phosphopeptide binding. This affirms that the C2-iSH2 inhibitory contact site does not function identically to the nSH2 inhibitory site, which includes both C2 and helical domains in the crystal structure (Mandelker et al., 2009) . The degree of activation is enhanced by increase in negative charges on the liposomes. Both anionic lipids PS and PtdIns(4,5)P 2 enhance lipid binding.
There is a pattern correlating the location of the mutations with their hydrophobic component of lipid binding (Figure 3j ): non-kinase domain mutants (C420R, E545K and p85a-N564D) display high levels of hydrophobic interaction with neutral lipids in the basal state, whereas the kinase C-terminal mutants require phosphopeptide activation to achieve the same level of hydrophobic binding. We will consider the two groups separately.
Despite their different chemical properties, the kinase domain mutants, H1047L, H1047R and G1049R, exhibit similarly high levels of hydrophobic binding to neutral lipids, and electrostatic binding to PS/ PtdIns(4,5)P 2 -containing lipids upon phosphopeptide activation. These binding levels are a few folds higher than those of the activated WT enzyme. We have shown that the kinase helix ka12 constitutes a lipid-binding site. It is likely that helix ka11 and the ka11-ka12 'elbow', on which these mutations reside, is an extension of the same site.
For non-kinase domain mutants, the nature of the effects of hydrophobicity is not immediately obvious.
Disruption of the C2-iSH2 (C420R and p85a-N564D) or the C2/helical-nSH2 contacts (E545K) could expose hydrophobic regions in the C2 domain that are normally inaccessible to lipid binding. The iSH2 N564 forms polar contacts with the C2 N345, which is in the C2b1-b2 loop. The C2 C420, which is in the C2b5-b6 loop, forms van der Waals contacts with iSH2 P568 (Figure 3a) . These two C2 loops in p110a are equivalent to the lipid-binding loops in the C2 domains of PKCa, which binds to PS (Guerrero-Valero et al., 2009), and of cPLA 2 , which binds to phosphatidylcholine Stahelin et al., 2003) . Superposition of the PKCa C2 structure, which has a bound short acyl-chain PS molecule (PDB ID: 1dsy), onto the C2 domain of our p110a/p85a-iSH2 structure reveals that both N564D and C420R would be compatible with accessing phospholipid headgroups (Supplementary Figure S4a) . This interpretation would account for the observed increase in electrostatic interaction with anionic lipids (Figure 3j ).
Global conformational change in p110a accompanies nSH2 disengagement
The p85a nSH2 does not contact the lipid-binding elements in the kinase C-lobe (Figure 4a ) but appears to control their access to membrane (Figures 3f-j) . This suggests the activation mechanism by nSH2 to be allosteric. By performing structural alignments on the iSH2 of p110a/p85a structures, we observe a global conformational difference between those lacking the inhibitory contacts with nSH2 (as represented by the WT p110a/p85a-iSH2 structures) and those with the nSH2 interactions (as represented by the H1047R p110a/p85a-niSH2 structures; Figures 4b and c) . Viewing down the iSH2 coiled-coil axis from the nSH2 side, the p110a subunit rotates clockwise from the state with an ordered nSH2 to the state lacking the nSH2 (Figure 4c) . The adaptor-binding domain and the C2, which are anchored on the iSH2, form the pivot points of the movement (Figure 4d) . The movement appears to be transmitted from the helical domain to the Ras-binding domain and the kinase C-lobe, which exhibit the greatest degree of displacement (Figure 4d ). This global conformational change suggests how nSH2 disengagement from p110a could allosterically cause local conformational change in the kinase C-lobe that might impact on activity. This is noteworthy considering that our WT p110a/p85a-iSH2/PIK-108 structure and the apo WT p110a/p85a-iSH2 structure experience very different crystal packing environments but superimpose well (Figure 4b ).
Activation of all class IA PI3Ks by phosphopeptide increases lipid binding Activation of p110b/p85a-nicSH2 and p110d/p85a-nicSH2 complexes by phosphopeptide also induces lipid binding (Figure 5a ). This is in agreement with the recent report for p110d in a complex with full-length p85a (Burke et al., 2011) . The relative contributions of electrostatic and hydrophobic components of binding differ among the three p110 isoforms, probably reflecting their sequence variability in the key lipid-binding sites (Figure 1 ). In the primary sequences, the equivalent of H1047 in p110a is a Leu in p110b and p110d. For PS/ PtdIns(4,5)P 2 -containing liposomes, the total lipidbinding level of activated H1047L p110a is a few fold higher than those of activated p110b and p110d (Figure 5b ). These results indicate that there is more than this hotspot position that differentiates the lipidbinding capabilities among the three p110 isoforms.
Discussion
We have directly demonstrated that phosphopeptideinduced lipid binding underlies the activation mechanism for WT p110a/p85a. For most cancer-linked mutants of p110a/p85a, both basal and phosphopeptide-induced membrane binding is enhanced. For WT p110a, the primary lipid-binding sites reside in the kinase domain, comprising the polybasic activation loop and hydrophobic elements in the C-terminal tail. We have identified activating cancer-linked mutants in the kinase C-terminal tail (H1047L, H1047R and G1049R) as well as mutants affecting the C2-iSH2 interaction (C420R and p85a-N564D) that enhance intrinsic lipid binding. Our binding data and structural analysis support the dual roles of C420R and N564D in disrupting C2-iSH2 contact and enhancing lipid binding. It is likely that this occurs via direct interactions between the C2 and/or the iSH2 domains with membranes. This additional membrane-binding site could both enhance total lipid binding and influence the choice of the membrane used by the WT enzyme or by particular p110a/p85a mutants in a cellular context. Our data indicate that the inhibitory contact formed between the nSH2 and p110a C2/helical/kinase domains suppresses the basal kinase activity by inhibiting membrane binding. This is consistent with previous biochemical results for enzyme activity (Yu et al., 1998) , in that the p85a nSH2, but not the cSH2, has a principal role in regulating the activity of p110a. Mechanistically, we postulate that relieving the nSH2 inhibitory contact from p110a could result in a concerted conformational change propagating from the helical domain to the kinase C-lobe, as suggested by our structural comparison of activated and inhibited forms of p110a/p85a (Figure 4 ). This might trigger the activation loop and the C-terminal region to adopt lipid-binding competent conformations. The polybasic activation loop both facilitates long-range electrostatic attraction to anionic lipids and positions the PtdIns(4,5)P 2 headgroup to the bound ATP for phosphoryl transfer. As the ATPbinding pocket is recessed in the kinase domain, partial membrane penetration by the C-terminal region would facilitate approach of the ATP g-phosphate to the inositol ring of PtdIns(4,5)P 2 ( Figure 6 ).
We have demonstrated that binding of activated p110/p85a to lipid membrane has both an electrostatic and a hydrophobic component. Basic residues in the activation loop contribute to the electrostatic component. The C-terminal tail is clearly important for membrane interaction, but its contribution is complex. Surface plasmon resonance measurements show that mutating the hydrophobic WIF motif to 'AAA' abolishes measurable electrostatic interactions with anionic lipids. Conversely, the activated H1047L, H1047R and G1049R mutants increase both hydrophobic and electrostatic interactions with lipids. These observations attest to the importance of cooperation between the electrostatic and the hydrophobic membrane-binding elements in p110a/p85a, as seen for other membrane-binding proteins (Cho and Stahelin, 2005) . Our data also elucidate the influence of lipid composition on lipid kinase activities for both WT and mutant p110/p85 complexes (Mandelker et al., 2009) .
Our structure reveals an alternative, small-molecule binding site in the kinase C-lobe. Current inhibitors for class I PI3K are all ATP-competitive compounds (Marone et al., 2008) . This induced binding pocket might be exploited to develop a novel class of inhibitors that are not ATP competitive but could interfere with membrane binding. Although we could not detect any inhibition of lipid binding with PIK-108 (up to 50 mM for the CD_E545K mutant, assayed in the same manner described in Figures 3i and j, data not shown) , it might be that compounds with enhanced affinity for this site could act as PI3K inhibitors. An example of a membrane-binding inhibitor that is in clinical trials is perifosine, an alkylphospholipid that targets the PH domain of AKT (Gills and Dennis, 2009 ).
It appears that the p110a and p85a mutations can be classified as two basic types: (1) those that relieve p85-mediated inhibition and (2) those that lead to additional lipid-binding capability (Figure 6 ). Type I mutations upregulate kinase activity by unmasking the intrinsic lipid-binding potential of WT p110a/p85a. These (Verdaguer et al., 1999) , 1w2c (Gonzalez et al., 2004) and 1e8x (Walker et al., 1999) . Details of how PS, IP3 and ATP were docked and modelling of the kinase C-terminal helices are illustrated in Supplementary Figure S4 . The Ca atoms of the labelled residues are represented in spheres. For clarity, the kinase domain N-lobe is coloured red in the right panel only, and the helical domain is green on the left panel only. Type I activating cancer-linked mutations that are shown or predicted to relieve the p85a adaptorbinding domain-mediated inhibition are highlighted in orange (the mutations that we predict would be type I, but have not been tested are underlined). The type II mutants, which are RTK hyperactivatable, are highlighted in pink. Note that docking of PS is solely for the purpose of approximating the lipid-binding site in the p110a C2 domain, and does not imply that this domain binds PS specifically.
mutants have elevated basal activities, and binding of RTK phosphopeptides does not significantly enhance their activities beyond that of activated WT enzyme. We have shown that the hotspot mutant E545K belongs to this class, in accordance with previous work (Miled et al., 2007; Carson et al., 2008) . Several other activating mutations that are distant from the putative membrane interface, such as R38C/H, R88Q, P539R, and deletion of residues 449-455 in the C2b7-b8 loop (Ikenoue et al., 2005; Oda et al., 2008; Rudd et al., 2011) , could also belong to this class ( Figure 6 ). Type II mutations are still subjected to p85a nSH2-mediated inhibition. We and others have shown that H1047R belongs to this type, which can be significantly activated by a phosphorylated RTK peptide (this study) or the adaptor protein IRS (Carson et al., 2008) . Although basal activities of type II mutants are higher than that of WT enzyme, their maximal lipid-binding and kinase activities achieved by RTK phosphopeptide binding greatly exceed than those of the activated WT enzyme (three-to sevenfold with our experimental setup). Our in vitro results imply that the biological outputs of the type II mutants can be greatly augmented by growth factor/RTK signalling. This notion is supported by reports that compared the E545K with H1047R mutants in cells. Human cancer cell lines bearing helical domain mutations showed lower AKT phosphorylation level and AKTdependent signalling than cell lines bearing kinase domain mutations coupled with either HER2 amplification or epidermal growth factor receptor hyperactivation (Vasudevan et al., 2009) . H1047R, but not E545K, was found to enhance HER2-mediated transformation of breast cancer cells via autocrine proliferative stimulation (Chakrabarty et al., 2010) . Therefore, cancers with the type II mutations might be better treated by co-inhibition of p110a and RTKs, because these mutants strongly depend on RTK stimulation to reach a critical threshold of membrane binding/activity necessary for transformation. For E545K to achieve a similar level of transforming activity as H1047R in chicken embryonic fibroblasts, it required additionally Ras binding (Zhao and Vogt, 2008) . It is likely that Ras could increase recruitment of p110a to lipid membrane. Cancers with type I mutations, such as E545K, might be better treated by co-inhibition of the p110a and the Ras pathway, because these mutants could be more dependent on 'topping up' by Ras to achieve the membrane binding threshold necessary for transformation. Type I and type II mutants could also confer distinct functional significance during different stages of cancer biology. For example, the E545K mutant was found to have a stronger metastatic phenotype than the H1047R mutant in tumour xenograft models using isogenic, human breast cancer cells (Pang et al., 2009) . The ability to induce tumour formation thus far has been demonstrated only for the H1047R mutant, but not yet for the E545K mutant, in engineered mouse models of cancers (Engelman et al., 2008; Adams et al., 2011; Meyer et al., 2011) .
Both growth factor independence and growth factor signalling manipulation are traits that enable cancer cells to sustain proliferative signalling (Witsch et al., 2010; Hanahan and Weinberg, 2011) . Investigating the influence of upstream RTK signalling could elucidate the yet unclear roles of the different PI3K mutations in cancer initiation, progression and maintenance, and in identifying suitable biomarkers for cancer therapy targeting the PI3K pathway (Engelman, 2009 ).
Materials and methods
Plasmids
Details of expression constructs for p110a, p110b, p110d (all mouse), p85a (mouse, except for the 'ni' fragment which is human) and Grp1-PH (human) are provided in Supplementary materials and methods. Domain boundaries of p85a fragments are shown in Figure 1 .
Protein expression and purification All p110/p85 complexes were co-expressed in Sf9 insect cells. The N-terminal His 6 tag on p110a was kept for proteins used for crystallization but was cleaved off for those used for functional analyses. GST-Grp1-PH was expressed in Escherichia coli. Details of expression and purification are described in Supplementary materials and methods.
Crystallization and structure determination
The complex of His 6 -(TEV)-tagged mouse p110a with human p85a-niSH2 was co-crystallized with PIK-108. The crystals diffracted to 3.5 Å , and belong to the space group I222 with one heterodimer per asymmetric unit. The human apo WT p110a/ p85a-iSH2 structure ( (Huang et al., 2007) , PDB ID: 2rd0) was used as the search model for molecular replacement. Details of crystallization and structure determination are described in Supplementary materials and methods. Crystallographic statistics are presented in Supplementary Table S1. All structural graphics were prepared with PyMOL (http://www.pymol.org).
Lipid kinase activity assay Liposomes comprising phosphatidylcholine/phosphatidylethanolamine/PS/PtdIns(4,5)P 2 /cholesterol were in mol% ratios of either 38:25:20:2:15 or 38:35:10:2:15. PtdIns(3,4,5)P 3 production was measured by a modified fluorescence polarization assay (Echelon Biosciences, Salt Lake City, UT, USA), originally developed for use with diC8-PtdIns(4,5)P 2 as a substrate (Drees et al., 2003) . Reactions were carried out at room temperature (25 1C) in 384-well microtitre plates. A 10-ml reaction consisted of 50 mM PtdIns(4,5)P 2 in 2.5 mM liposomes, p110/p85 (500 nM for non-activated WT p110a/p85a-nicSH2, 5 nM for the rest), 100 mM ATP, 1 mM MgCl 2 and with or without 1 mM pY2-peptide. The reactions were quenched with 5 ml buffer containing 20 mM Hepes (pH 7.5), 150 mM NaCl, 20 mM EDTA and 400 nM GST-Grp1-PH, followed by addition of 5 ml of 40nM TAMRA-Ins(1,3,4,5)P 4 in HNT buffer. The plates were read in a PHERAstar spectrofluorometer (BMG Labtech, Ortenberg, Germany) using the FP/540-20/590-20/590-20 optical module. Standard curves were performed with diC8-PtdIns(3,4,5)P 3 with or without pY2-peptide. Only a minor difference due to presence of pY2-peptide was observed under our assay condition, which is different from that published previously (Carson et al., 2008) .
Surface plasmon resonance measurement of lipid binding Liposome-binding experiments were performed at 25 1C on a BIAcore2000, using the L1 sensor chip (GE Healthcare, Chalfont St Giles, UK). HNT was used as the running buffer. Liposomes comprising phosphatidylcholine/phosphatidyletha-nolamine/PS/PtdIns(4,5)P 2 /cholesterol were in mol% ratios of either 60:25:0:0:15 (Fc1), 50:25:10:0:15 (Fc2), 48:25:10:2:15 (Fc3) or 38:25:20:2:15 (Fc4). Liposomes (0.1-0.2 mM) were injected into each flow cell at 5 ml/min flow rate to achieve B3400 RU immobilization level. This was followed by two injections of 0.2 M Na 2 CO 3 to remove loosely bound liposomes. Chicken egg white albumin (0.2 mg/ml) was injected over the flow cells to mask any residual hydrophobic surface not covered by the liposomes, followed by multiple injections of 0.2 M Na 2 CO 3 to stabilize the baseline. Steady-state binding was measured by injecting p110/p85 complexes (concentration at either 500 nM or 1 mM) at 2 ml/min flow rate for 5 min. Each measurement was followed by injections of 0.2 M Na 2 CO 3 to regenerate the liposome surface. Independent experiments were carried out with freshly immobilized liposomes after stripping the sensor surface sequentially with 0.1 N NaOH, isopropanol:0.1 N NaOH (2:3) and 6 M guanidine HCl.
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Atomic coordinates for the reported crystal structure has been deposited with the Protein Data Bank under accession code 4A55.
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